Evidence map›Paper›PMID 32529585›Full record

ArticleInternational journal of hematology2020

Impact of prednisolone dosage in the CHOP regimen for follicular lymphoma: a retrospective study.

Takashi Ikeda, Shin-Ichiro Fujiwara, HIrotomo Nakajima, Shin-Ichiro Kawaguchi, Yumiko Toda, Shoko Ito, Shinichi Ochi, Takashi Nagayama, Kiyomi Mashima, Kento Umino and 13 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 1 institution in 1 country.

Takashi IkedaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Shin-Ichiro FujiwaraDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
HIrotomo NakajimaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Shin-Ichiro KawaguchiDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Yumiko TodaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Shoko ItoDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Shinichi OchiDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Takashi NagayamaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Kiyomi MashimaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Kento UminoDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Daisuke MinakataDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Hirofumi NakanoDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Kaoru MoritaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Ryoko YamasakiDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Yasufumi KawasakiDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Masahiro AshizawaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Chihiro YamamotoDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Kaoru HatanoDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Kazuya SatoDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Iekuni OhDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Ken OhmineDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Kazuo MuroiDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan.
Yoshinobu KandaDivision of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotuke, Tochigi, 329-0498, Japan. ycanda-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-4866-9307
Jichi Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is one of the standard regimens for indolent B-cell non-Hodgkin's lymphoma (NHL). It is unclear whether the prednisolone (PSL) dosage affects the therapeutic effect or the adverse event profile. We retrospectively examined 48 patients with indolent B-cell NHL who were treated with R-CHOP (PSL 50 mg/m

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsBody Surface AreaCyclophosphamideDisease-Free SurvivalDoxorubicinDrug Dosage CalculationsFemaleHumansLymphoma, FollicularLymphoma, Non-HodgkinMaleMiddle AgedPrednisolonePrednisoneCyclophosphamideDoxorubicinPrednisolonePrednisoneR-CHOP protocolRituximabVincristineChemotherapyMalignant lymphomaPrednisolone dosage

Identifiers

PMID32529585
OpenAlexW3034997157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.